Ankit Mahadevia

2022

In 2022, Ankit Mahadevia earned a total compensation of $4.2M as Former President and Chief Executive Officer at Spero Therapeutics, a 13% decrease compared to previous year.

Compensation breakdown

Bonus$254,000
Non-Equity Incentive Plan$342,900
Option Awards$1,499,324
Salary$633,750
Stock Awards$1,499,998
Other$9,733
Total$4,239,705

Mahadevia received $1.5M in stock awards, accounting for 35% of the total pay in 2022.

Mahadevia also received $254K in bonus, $342.9K in non-equity incentive plan, $1.5M in option awards, $633.8K in salary and $9.7K in other compensation.

Rankings

In 2022, Ankit Mahadevia's compensation ranked 808th out of 5,756 executives tracked by ExecPay. In other words, Mahadevia earned more than 86.0% of executives.

ClassificationRankingPercentile
All
808
out of 5,756
86th
Division
Manufacturing
367
out of 3,133
88th
Major group
Chemicals And Allied Products
124
out of 1,419
91st
Industry group
Drugs
111
out of 1,320
92nd
Industry
Pharmaceutical Preparations
82
out of 966
92nd
Source: SEC filing on September 1, 2023.

Mahadevia's colleagues

We found two more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2022.

2022

Satyavrat Shukla

Spero Therapeutics

Chief Executive Officer

2022

Tamara Joseph

Spero Therapeutics

Chief Legal Officer

News

You may also like